Expectations trend
FY2028 · fiscal year ending 2028-09-30 · fmp
Outlook Therapeutics Inc (OTLK)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.44-4.98%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.33 → 0.57 EPS · FY ending Sep 30, 2028 · 1 analyst
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 6, 2026 to Nov 5, 2026: (new ÷ prior − 1). Contributor count changed from 1 to 1; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for OTLK yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Raise capital to support operations and liquidity | A supporting condition in Outlook Therapeutics Inc's published investment case. The stated target is Issue at least 8.5 million shares in 2026-Q2. | Intact | Fails to raise needed capital to fund operations in 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-09-30 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Dec 18, 2026
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making commercialization story, not a proven durable compounder. The long-term thesis is intact, with medium confidence, as the U.S. launch preparation advances; management execution has been volatile and European progress is mixed.
The evidence characterizes OTLK as cheap versus peers, but valuation-model confidence is low. The snapshot does not specify what expectations the market already assumes, so the expectations gap is unclear.
Near term, continued launch investment is likely to keep results loss-making; the latest reported quarterly net loss was $20.3 million. Management plans a U.S. launch by the end of 2026, while European unit sales were down about 10% in the second quarter before trending upward early in the third. A potential guidance cut, a weakening jobs picture, and a recent notice related to continued listing rules are risks to monitor.
Over the next one to three years, the thesis hinges on executing the U.S. launch and expanding European commercialization while managing costs. The unfavorable scenario is weaker guidance or broader economic concerns weighing on healthcare names; the favorable scenario is continued strength in sector bellwethers supporting sector momentum.
OTLK’s multi-year view rests on turning regulatory approval and launch preparation into sustained commercialization, while the business remains loss-making and execution risks are high. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in Outlook Therapeutics Inc's published investment case. The stated target is Launch LYTENAVA in Switzerland in 2027. |
| Improving |
| No launch or FDA approval by end of 2027 |
Qualitative condition This condition has no defined numerical measure. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Reduce operating losses and improve net income and cash flow | Losses are getting smaller, with net income improving by $8.8M. | Intact | Losses worsen beyond 2025-Q4 levels over next 4 quarters | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.33 → $0.57 · observed estimates
$0.17B → $0.27B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-10-01 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-10-02 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-10-03 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-10-04 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-10-05 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-10-06 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-10-07 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-10-08 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-10-09 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-10-10 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-10-11 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-10-12 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-10-13 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-10-14 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-10-15 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-10-16 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-10-17 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-10-18 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-10-19 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-10-20 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-10-21 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-10-22 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-10-23 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-10-24 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-10-25 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-10-26 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-10-27 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-10-28 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-10-29 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-10-30 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-10-31 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-11-01 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-11-02 | $0.33 | $170,653,000 | 1 / 2 |
| 2026-11-03 | $0.57 | $268,000,000 | 1 / 2 |
| 2026-11-04 | $0.57 | $268,000,000 | 1 / 2 |
| 2026-11-05 | $0.57 | $268,000,000 | 1 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.